Evidence map›Paper›PMID 24470137›Full record

SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014

Association of X-ray repair cross-complementing group 1 promoter rs3213245 polymorphism with lung cancer risk.

Ruotian Wang, Yi Zhang, Jian Zhang, Xiuyi Zhi

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruotian WangThoracic Department, Xuanwu Hospital of Capital Medical University (CMU), Beijing, 100053, China.
Yi Zhang
Jian Zhang
Xiuyi Zhi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-ray repair cross-complementing group 1 (XRCC1) is a major DNA repair protein in the base excision repair pathway. XRCC1 rs3213245 is a functional polymorphism in the XRCC1 gene promoter region which results in decreased DNA repair capacity. Previous studies investigating the association of XRCC1 rs3213245 polymorphism with lung cancer risk reported conflicting results. A meta-analysis of published studies was performed to provide a comprehensive assessment of the association. The pooled odds ratio (OR) with its 95% confidence interval (95% CI) was calculated to assess the association. Subgroup analysis was performed by ethnicity. Finally, six studies with a total of 3,208 cases and 3,505 control studies were included into our meta-analysis. The pooled results showed that there was a significant association between XRCC1 rs3213245 polymorphism and lung cancer risk (allele model: OR =1.31, 95% CI 1.13-1.51, P < 0.001; homozygote model: OR = 1.42, 95% CI 1.13-1.79, P = 0.003; recessive model: OR = 1.39, 95% CI 1.13-1.71, P = 0.002; dominant model: OR = 1.31, 95% CI 1.17-1.47, P < 0.001). Subgroup analysis by ethnicity showed that the association was still significant in both Asians (all P values less than 0.05) and Caucasians (recessive model: OR = 1.26, 95 % CI 1.01-1.59, P = 0.045). Thus, there is a significant association of XRCC1 rs3213245 polymorphism with lung cancer risk.

Indexed as

DNA-Binding ProteinsGenetic Association StudiesGenetic Predisposition to DiseaseHumansLung NeoplasmsOdds RatioPolymorphism, Single NucleotidePromoter Regions, GeneticRisk FactorsX-ray Repair Cross Complementing Protein 1DNA-Binding ProteinsX-ray Repair Cross Complementing Protein 1XRCC1 protein, human

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.